Pfizer (NYSE:PFE) said on Friday that a late-stage trial evaluating a Braftovi combination increased survival time for patients with metastatic colorectal cancer with a BRAF V600E mutation.
In the study, Braftovi in combination with Erbitux and mFOLFOX6, showed 51% risk reduction in death